OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- OCI-AML2
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- ccle_lineage_sub_subtype
- M4
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.888 |
| 2 | KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.886 |
| 3 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.862 |
| 4 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.858 |
| 5 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.844 |
| 6 | TCGA-CR-6487-01A-11R-1873-07 | — | — | 0.838 |
| 7 | MBCProject_1542_T2_RNA | — | D | 0.830 |
| 8 | NOMO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.821 |
| 9 | SRR8518222 | — | D | 0.806 |
| 10 | HNT34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.764 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.405 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.222 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.174 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.116 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.066 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.052 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.052 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.037 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.025 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.008 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.004 | Inavolisib | — uncovered |